HEART TRANSPLANTATION Overall ISHLT 2003 J Heart Lung
- Slides: 86
HEART TRANSPLANTATION Overall ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
NUMBER OF HEART TRANSPLANTS REPORTED BY YEAR AND LOCATION ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
AVERAGE CENTER VOLUME Heart Transplants: January 1, 1998 - June 30, 2002 ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
HEART TRANSPLANTS: Donor Age by Year of Transplant ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
Transplants % of Tr AGE DISTRIBUTION OF HEART RECIPIENTS (1/1982 -6/2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
AGE DISTRIBUTION OF HEART TRANSPLANT RECIPIENTS BY ERA 1985 -1996 ISHLT 1/1997 -6/2002 2003 J Heart Lung Transplant 2003; 22: 610 -72.
HEART TRANSPLANTATION Actuarial Survival (1/1982 -6/2001) Half-life = 9. 3 years Conditional Half-life = 12. 0 years N=59, 391 ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
HEART TRANSPLANTATION Adult Recipients ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
DIAGNOSIS IN ADULT HEART TRANSPLANTS ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Survival (%) Actuarial Survival by Era ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72. (Transplants: 1/1982 -6/2001)
ADULT HEART TRANSPLANTATION Actuarial Survival by Age Group (Transplants: 1/1982 -6/2001) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72. (Transplants: 1/1982 -6/2001)
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis (Transplants: 1/1994 -6/2001) Age = 18 -34 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis (Transplants: 1/1994 -6/2001) Age = 35 -49 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis (Transplants: 1/1994 -6/2001) Age = 50 -64 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis (Transplants: 1/1994 -6/2001) Age = 65 -69 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by Diagnosis (Transplants: 1/1994 -6/2001) Age = 70+ Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTATION Actuarial Survival by PVR ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72. (Transplants: 4/1994 -6/2001)
ADULT HEART TRANSPLANTATION Actuarial Survival by PVR (Transplants: 4/1994 -6/2001) During first 6 months following transplantation ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72. 22 286 35 98 64 91 31 29 32 18 123 172 ADULT HEART RE-TRANSPLANTS 1 -Year Survival
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Recipient Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Donor Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Donor Weight ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Recipient Height ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Center volume ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Ischemia time ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Bilirubin ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Recipient creatinine ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality Cardiac Output ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality PVR ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Risk Factors for 1 Year Mortality PA Diastolic ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Factors Not Significant for 1 Year Mortality Recipient Factors: VAD, ABO identical/compatible, symptomatic cerebrovascular disease/cerebrovascular event, pneumothorax, pregnancy, pulmonary embolism, PA systolic, PCW, history of malignancy, weight ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/2001) Factors Not Significant for 1 Year Mortality Donor Factors: Gender, clinical infection, history of cancer, history of hypertension, history of diabetes, height Transplant Factors: Donor/recipient BMI ratio, donor/recipient height ratio, CMV mismatch ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1995 -6/1997) Risk Factors for 5 Year Mortality (N=8, 271) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Recipient Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Donor Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Donor BMI ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Recipient Height ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Most Recent PRA ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Center volume ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Ischemia time ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Bilirubin ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Recipient creatinine ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality PCW ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Factors Not Significant for 5 Year Mortality Recipient Factors: VAD, ventilator, in hospital, IV inotropes, balloon, ABO identical/compatible, symptomatic cerebrovascular disease/cerebrovascular event, pneumothorax, pregnancy, pulmonary embolism, PA systolic, PA diastolic, PVR, history of malignancy, weight, gender, history of malignancy ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Factors Not Significant for 5 Year Mortality Donor Factors: Gender, cause of death, clinical infection, history of cancer, history of hypertension, history of diabetes Transplant Factors: Donor/recipient BMI ratio, donor/recipient height ratio, CMV mismatch, HLA mismatch ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=6, 273) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Recipient Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Donor Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Donor BMI ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year Recipient creatinine ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Factors Not Significant for 5 Year Mortality Conditional on Survival to 1 Year Recipient Factors: VAD, ventilator, in hospital, IV inotropes, balloon, ABO identical/compatible, symptomatic cerebrovascular disease/cerebrovascular event, pneumothorax, pregnancy, pulmonary embolism, PA systolic, PA diastolic, PCW, PVR, history of malignancy, height, weight, gender, history of malignancy, PRA, bilirubin ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Factors Not Significant for 5 Year Mortality Conditional on Survival to 1 Year Donor Factors: Gender, cause of death, clinical infection, history of cancer, history of hypertension, history of diabetes Transplant Factors: Donor/recipient BMI ratio, donor/recipient height ratio, CMV mismatch, HLA mismatch, center volume, ischemia time Post-transplant Factors: Dialysis, prolonged graft dysfunction, permanent pacemaker ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Functional Status (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Employment Status (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Rehospitalization Post-transplant (Follow-ups: April 1994 - June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Induction Immunosuppression (Follow-ups: January 2000 – June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Induction Immunosuppression (Follow-ups: January 2000 - June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Maintenance Immunosuppression at Any Time During Follow-up Period For follow-ups between January 2000 through June 2002 ISHLT NOTE: Different patients are analyzed in Year 1 and Year 5 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2000 through June 2002 ISHLT NOTE: Different patients are analyzed in Year 1 and Year 5 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2000 through June 2002 ISHLT NOTE: Different patients are analyzed in Year 1 and Year 5 2003 J Heart Lung Transplant 2003; 22: 610 -72.
POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
POST-HEART TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 5 Years Post-Transplant (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
Freedom from CAV and Freedom from Severe Renal Dysfunction* For Adult Heart Recipients (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
MALIGNANCY POST-HEART TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April 1994 -June 2002) Malignancy/Type 1 -Year Survivors 5 -Year Survivors No Malignancy 13699 (96. 7%) 3728 (82. 0%) 470 (3. 3%) 821 (18. 0%) Malignancy (all types combined) Malignancy Type Skin 206 499 Lymph 113 72 Other 103 158 Lymph + Skin 12 Lymph + Other 13 Skin + Other 26 Lymph + Skin + Other 2 Type Not Reported 48 ”Other” includes: prostate (11), adenocarcinoma (7), lung (5), bladder (4), breast (2), cervix (2), colon (2), head/neck/throat (2), renal (2). ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72. 39
Freedom from Malignancy For Adult Heart Recipients (Follow-ups: April 1994 -June 2002) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years (N=4, 797) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years Recipient Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years Donor Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years Donor BMI/Recipient BMI ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV within 5 Years Center volume ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV between 5 and 7 Years (N=839) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (4/1994 -6/1997) Risk Factors for Developing CAV between 5 and 7 Years Donor BMI ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for Developing Malignancy within 5 Years (N=4, 371) ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for Developing Malignancy within 5 Years ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for Developing Malignancy within 5 Years Recipient Age ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANTS (1/1995 -6/1997) Risk Factors for Developing Malignancy within 5 Years Donor BMI ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
ADULT HEART TRANSPLANT RECIPIENTS: Cause of Death (Deaths: January 1992 - June 2002) CAUSE OF DEATH 0 -30 Days (N = 2, 454) 31 Days - 1 Year (N = 2, 155) >1 Year - 3 Years (N = 1, 642) >3 Years - 5 Years (N = 1, 391) >5 Years (N = 3, 454) CAV 44 (1. 8%) 108 (5. 0%) 243 (14. 8%) 251 (18. 0%) 588 (17. 0%) ACUTE REJECTION 157 (6. 4%) 264 (12. 3%) 156 (9. 5%) 60 (4. 3%) 39 (1. 1%) LYMPHOMA 1 (0. 0%) 44 (2. 0%) 78 (4. 8%) 79 (5. 7%) 181 (5. 2%) MALIGNANCY, OTHER 2 (0. 1%) 49 (2. 3%) 171 (10. 4%) 269 (19. 3%) 661 (19. 1%) CMV 3 (0. 1%) 27 (1. 3%) 14 (0. 9%) 3 (0. 2%) 4 (0. 1%) INFECTION, NON-CMV 348 (14. 2%) 745 (34. 6%) 216 (13. 2%) 138 (9. 9%) 333 (9. 6%) PRIMARY FAILURE 602 (24. 5%) 183 (8. 5%) 118 (7. 2%) 67 (4. 8%) 191 (5. 5%) GRAFT FAILURE 403 (16. 4%) 226 (10. 5%) 282 (17. 2%) 201 (14. 5%) 466 (13. 5%) TECHNICAL 183 (7. 5%) 24 (1. 1%) 15 (0. 9%) 17 (1. 2%) 36 (1. 0%) OTHER 83 (3. 4%) 103 (4. 8%) 114 (6. 9%) 97 (7. 0%) 205 (5. 9%) 342 (13. 9%) 204 (9. 5%) 80 (4. 9%) 73 (5. 2%) 270 (7. 8%) RENAL FAILURE 14 (0. 6%) 16 (0. 7%) 27 (1. 6%) 44 (3. 2%) 203 (5. 9%) PULMONARY 109 (4. 4%) 71 (3. 3%) 72 (4. 4%) 51 (3. 7%) 128 (3. 7%) CEREBROVASCULAR 163 (6. 6%) 91 (4. 2%) 56 (3. 4%) 41 (2. 9%) 149 (4. 3%) MULTIPLE ORGAN FAILURE ISHLT 2003 J Heart Lung Transplant 2003; 22: 610 -72.
Bone marrow transplantation sri lanka
Types of transplant
Law of transplantation
Stem cell or bone marrow transplantation bangkok
Patrick evrard transplantation
Cultural transposition
Overall well done
Overall materiality adalah
Overall compositie
Pb(no3)2 + ki
Overall cas progress
Purpose of discussion
Project overall status
Overall rate law of a reaction
Guimera
Overall audit plan
Overall checking
What does carbonara smell like
Median overall survival
Literary mood
What is the range of the melody tonight
Overall procedure
Romeo and juliet theme analysis
Overall survival icon
Chapter 1 lesson 1 your total health lesson 1 quiz
The overall heat transfer coefficient
Satisfactory factory layout
Overall audit plan
First screen feasibility analysis example
Overall structure
The overall goal
The overall goal of science is
Overall cas progress
Citric acid cycle overall reaction
Theme is the message
Project overall status
Chapter 7 business management
Management prowess example
Overall process
Project overall status
Overall agenda
The overall plan or structure of music
Overall consistency
Molecularity of reaction
How to calculate performance materiality
Overall audit plan
Modernism vs naturalism
Project overall status
Overall reaction of cellular respiration
Serve to a general overall picture of the field of view
Glycolysis overall reaction
Overall structure
Qp=qv+nrt
Feudal japan
Project overall status
Five elements of hair design
Krebs cycle net products
Testing overall ability
An information systems examines a firm's overall security
Overall agenda
It is the overall plan of action that guides a retailer.
Product/service desirability
Overall teacher judgement
Color shape texture
A carefully developed overall approach to leading
Charles maurice de talleyrand-périgord previous offices
The overall heat transfer coefficient
Overall force acting on an object
Literary elements tone
Macroscopic energy balance
Write the overall equation for photosynthesis using words
Project overall status
Three steps in aerobic cellular respiration
Overall scale
The overall reaction in a commercial heat pack
Overall rag status
People differentiation
A nation's overall plan for dealing
Which of the following is not part of overall biodiversity?
Overall equipment effectiveness
Overall width
Glycolysis overall reaction
Overall expression
Rag project management
Overall agenda
Chapter 3 feasibility analysis
Tube pitch formula
